nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Erlotinib—kidney cancer	0.314	0.409	CbGbCtD
Rifaximin—NR1I2—Paclitaxel—kidney cancer	0.287	0.375	CbGbCtD
Rifaximin—CYP3A4—Everolimus—kidney cancer	0.0485	0.0633	CbGbCtD
Rifaximin—CYP3A4—Temsirolimus—kidney cancer	0.0328	0.0428	CbGbCtD
Rifaximin—CYP3A4—Pazopanib—kidney cancer	0.0172	0.0225	CbGbCtD
Rifaximin—CYP3A4—Erlotinib—kidney cancer	0.0123	0.016	CbGbCtD
Rifaximin—CYP3A4—Paclitaxel—kidney cancer	0.0112	0.0147	CbGbCtD
Rifaximin—CYP3A4—Sorafenib—kidney cancer	0.00999	0.013	CbGbCtD
Rifaximin—CYP3A4—Vinblastine—kidney cancer	0.00987	0.0129	CbGbCtD
Rifaximin—CYP3A4—Vincristine—kidney cancer	0.0097	0.0127	CbGbCtD
Rifaximin—CYP3A4—Sunitinib—kidney cancer	0.0081	0.0106	CbGbCtD
Rifaximin—CYP3A4—Doxorubicin—kidney cancer	0.00606	0.00791	CbGbCtD
Rifaximin—Body temperature increased—Dactinomycin—kidney cancer	0.000136	0.00058	CcSEcCtD
Rifaximin—Asthenia—Sorafenib—kidney cancer	0.000135	0.000578	CcSEcCtD
Rifaximin—Malaise—Paclitaxel—kidney cancer	0.000134	0.000575	CcSEcCtD
Rifaximin—Hypoglycaemia—Doxorubicin—kidney cancer	0.000134	0.000574	CcSEcCtD
Rifaximin—Vertigo—Paclitaxel—kidney cancer	0.000134	0.000573	CcSEcCtD
Rifaximin—Syncope—Paclitaxel—kidney cancer	0.000134	0.000572	CcSEcCtD
Rifaximin—Hypersensitivity—Sunitinib—kidney cancer	0.000133	0.000571	CcSEcCtD
Rifaximin—Decreased appetite—Vincristine—kidney cancer	0.000133	0.00057	CcSEcCtD
Rifaximin—Pruritus—Sorafenib—kidney cancer	0.000133	0.00057	CcSEcCtD
Rifaximin—Vomiting—Erlotinib—kidney cancer	0.000133	0.000569	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000132	0.000566	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Vincristine—kidney cancer	0.000132	0.000566	CcSEcCtD
Rifaximin—Fatigue—Vincristine—kidney cancer	0.000132	0.000565	CcSEcCtD
Rifaximin—Rash—Erlotinib—kidney cancer	0.000132	0.000564	CcSEcCtD
Rifaximin—Dermatitis—Erlotinib—kidney cancer	0.000132	0.000564	CcSEcCtD
Rifaximin—Hyponatraemia—Doxorubicin—kidney cancer	0.000131	0.000563	CcSEcCtD
Rifaximin—Insomnia—Gemcitabine—kidney cancer	0.000131	0.000562	CcSEcCtD
Rifaximin—Headache—Erlotinib—kidney cancer	0.000131	0.000561	CcSEcCtD
Rifaximin—Tinnitus—Capecitabine—kidney cancer	0.000131	0.000561	CcSEcCtD
Rifaximin—Loss of consciousness—Paclitaxel—kidney cancer	0.000131	0.000561	CcSEcCtD
Rifaximin—Pain—Vincristine—kidney cancer	0.000131	0.00056	CcSEcCtD
Rifaximin—Constipation—Vincristine—kidney cancer	0.000131	0.00056	CcSEcCtD
Rifaximin—Pain in extremity—Doxorubicin—kidney cancer	0.000131	0.00056	CcSEcCtD
Rifaximin—Flushing—Capecitabine—kidney cancer	0.00013	0.000558	CcSEcCtD
Rifaximin—Cough—Paclitaxel—kidney cancer	0.00013	0.000557	CcSEcCtD
Rifaximin—Asthenia—Sunitinib—kidney cancer	0.00013	0.000556	CcSEcCtD
Rifaximin—Dyspnoea—Gemcitabine—kidney cancer	0.00013	0.000554	CcSEcCtD
Rifaximin—Nausea—Vinblastine—kidney cancer	0.000129	0.000553	CcSEcCtD
Rifaximin—Migraine—Doxorubicin—kidney cancer	0.000129	0.000551	CcSEcCtD
Rifaximin—Nausea—Everolimus—kidney cancer	0.000129	0.000551	CcSEcCtD
Rifaximin—Diarrhoea—Sorafenib—kidney cancer	0.000129	0.000551	CcSEcCtD
Rifaximin—Pruritus—Sunitinib—kidney cancer	0.000128	0.000548	CcSEcCtD
Rifaximin—Angiopathy—Capecitabine—kidney cancer	0.000127	0.000546	CcSEcCtD
Rifaximin—Myalgia—Paclitaxel—kidney cancer	0.000127	0.000543	CcSEcCtD
Rifaximin—Chest pain—Paclitaxel—kidney cancer	0.000127	0.000543	CcSEcCtD
Rifaximin—Arthralgia—Paclitaxel—kidney cancer	0.000127	0.000543	CcSEcCtD
Rifaximin—Mediastinal disorder—Capecitabine—kidney cancer	0.000127	0.000542	CcSEcCtD
Rifaximin—Decreased appetite—Gemcitabine—kidney cancer	0.000126	0.000541	CcSEcCtD
Rifaximin—Hypersensitivity—Dactinomycin—kidney cancer	0.000126	0.00054	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000126	0.000539	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000125	0.000537	CcSEcCtD
Rifaximin—Discomfort—Paclitaxel—kidney cancer	0.000125	0.000537	CcSEcCtD
Rifaximin—Fatigue—Gemcitabine—kidney cancer	0.000125	0.000536	CcSEcCtD
Rifaximin—Gastrointestinal pain—Vincristine—kidney cancer	0.000125	0.000536	CcSEcCtD
Rifaximin—Dizziness—Sorafenib—kidney cancer	0.000124	0.000533	CcSEcCtD
Rifaximin—Pain—Gemcitabine—kidney cancer	0.000124	0.000532	CcSEcCtD
Rifaximin—Constipation—Gemcitabine—kidney cancer	0.000124	0.000532	CcSEcCtD
Rifaximin—Nausea—Erlotinib—kidney cancer	0.000124	0.000532	CcSEcCtD
Rifaximin—Dry mouth—Paclitaxel—kidney cancer	0.000124	0.000531	CcSEcCtD
Rifaximin—Diarrhoea—Sunitinib—kidney cancer	0.000124	0.00053	CcSEcCtD
Rifaximin—Mental disorder—Capecitabine—kidney cancer	0.000123	0.000527	CcSEcCtD
Rifaximin—Asthenia—Dactinomycin—kidney cancer	0.000123	0.000526	CcSEcCtD
Rifaximin—Confusional state—Paclitaxel—kidney cancer	0.000123	0.000525	CcSEcCtD
Rifaximin—Malnutrition—Capecitabine—kidney cancer	0.000122	0.000523	CcSEcCtD
Rifaximin—Dehydration—Doxorubicin—kidney cancer	0.000122	0.000521	CcSEcCtD
Rifaximin—Anaphylactic shock—Paclitaxel—kidney cancer	0.000122	0.000521	CcSEcCtD
Rifaximin—Abdominal pain—Vincristine—kidney cancer	0.000121	0.000518	CcSEcCtD
Rifaximin—Body temperature increased—Vincristine—kidney cancer	0.000121	0.000518	CcSEcCtD
Rifaximin—Infection—Paclitaxel—kidney cancer	0.000121	0.000517	CcSEcCtD
Rifaximin—Flatulence—Capecitabine—kidney cancer	0.000121	0.000516	CcSEcCtD
Rifaximin—Dizziness—Sunitinib—kidney cancer	0.00012	0.000512	CcSEcCtD
Rifaximin—Feeling abnormal—Gemcitabine—kidney cancer	0.00012	0.000512	CcSEcCtD
Rifaximin—Shock—Paclitaxel—kidney cancer	0.00012	0.000512	CcSEcCtD
Rifaximin—Vomiting—Sorafenib—kidney cancer	0.00012	0.000512	CcSEcCtD
Rifaximin—Abdominal pain upper—Doxorubicin—kidney cancer	0.00012	0.000512	CcSEcCtD
Rifaximin—Nervous system disorder—Paclitaxel—kidney cancer	0.000119	0.000511	CcSEcCtD
Rifaximin—Rash—Sorafenib—kidney cancer	0.000119	0.000508	CcSEcCtD
Rifaximin—Dermatitis—Sorafenib—kidney cancer	0.000119	0.000507	CcSEcCtD
Rifaximin—Back pain—Capecitabine—kidney cancer	0.000118	0.000506	CcSEcCtD
Rifaximin—Skin disorder—Paclitaxel—kidney cancer	0.000118	0.000506	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000118	0.000505	CcSEcCtD
Rifaximin—Headache—Sorafenib—kidney cancer	0.000118	0.000504	CcSEcCtD
Rifaximin—Muscle spasms—Capecitabine—kidney cancer	0.000118	0.000503	CcSEcCtD
Rifaximin—Hyperhidrosis—Paclitaxel—kidney cancer	0.000118	0.000503	CcSEcCtD
Rifaximin—Diarrhoea—Dactinomycin—kidney cancer	0.000117	0.000502	CcSEcCtD
Rifaximin—Nasopharyngitis—Doxorubicin—kidney cancer	0.000117	0.000501	CcSEcCtD
Rifaximin—Anorexia—Paclitaxel—kidney cancer	0.000116	0.000496	CcSEcCtD
Rifaximin—Vomiting—Sunitinib—kidney cancer	0.000115	0.000493	CcSEcCtD
Rifaximin—Body temperature increased—Gemcitabine—kidney cancer	0.000115	0.000492	CcSEcCtD
Rifaximin—Tremor—Capecitabine—kidney cancer	0.000115	0.00049	CcSEcCtD
Rifaximin—Rash—Sunitinib—kidney cancer	0.000114	0.000489	CcSEcCtD
Rifaximin—Dermatitis—Sunitinib—kidney cancer	0.000114	0.000488	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—kidney cancer	0.000114	0.000488	CcSEcCtD
Rifaximin—Hypotension—Paclitaxel—kidney cancer	0.000114	0.000486	CcSEcCtD
Rifaximin—Ill-defined disorder—Capecitabine—kidney cancer	0.000113	0.000486	CcSEcCtD
Rifaximin—Headache—Sunitinib—kidney cancer	0.000113	0.000485	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—kidney cancer	0.000113	0.000484	CcSEcCtD
Rifaximin—Anaemia—Capecitabine—kidney cancer	0.000113	0.000484	CcSEcCtD
Rifaximin—Hypersensitivity—Vincristine—kidney cancer	0.000113	0.000483	CcSEcCtD
Rifaximin—Nausea—Sorafenib—kidney cancer	0.000112	0.000478	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000111	0.000474	CcSEcCtD
Rifaximin—Malaise—Capecitabine—kidney cancer	0.00011	0.000472	CcSEcCtD
Rifaximin—Insomnia—Paclitaxel—kidney cancer	0.00011	0.000471	CcSEcCtD
Rifaximin—Vertigo—Capecitabine—kidney cancer	0.00011	0.00047	CcSEcCtD
Rifaximin—Asthenia—Vincristine—kidney cancer	0.00011	0.00047	CcSEcCtD
Rifaximin—Syncope—Capecitabine—kidney cancer	0.00011	0.000469	CcSEcCtD
Rifaximin—Vomiting—Dactinomycin—kidney cancer	0.000109	0.000466	CcSEcCtD
Rifaximin—Dyspnoea—Paclitaxel—kidney cancer	0.000108	0.000464	CcSEcCtD
Rifaximin—Rash—Dactinomycin—kidney cancer	0.000108	0.000463	CcSEcCtD
Rifaximin—Nausea—Sunitinib—kidney cancer	0.000108	0.00046	CcSEcCtD
Rifaximin—Loss of consciousness—Capecitabine—kidney cancer	0.000108	0.00046	CcSEcCtD
Rifaximin—Cough—Capecitabine—kidney cancer	0.000107	0.000457	CcSEcCtD
Rifaximin—Dysuria—Doxorubicin—kidney cancer	0.000106	0.000453	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—kidney cancer	0.000106	0.000453	CcSEcCtD
Rifaximin—Decreased appetite—Paclitaxel—kidney cancer	0.000106	0.000453	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000105	0.00045	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000105	0.000449	CcSEcCtD
Rifaximin—Fatigue—Paclitaxel—kidney cancer	0.000105	0.000449	CcSEcCtD
Rifaximin—Diarrhoea—Vincristine—kidney cancer	0.000105	0.000448	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—kidney cancer	0.000105	0.000447	CcSEcCtD
Rifaximin—Asthenia—Gemcitabine—kidney cancer	0.000104	0.000446	CcSEcCtD
Rifaximin—Chest pain—Capecitabine—kidney cancer	0.000104	0.000446	CcSEcCtD
Rifaximin—Myalgia—Capecitabine—kidney cancer	0.000104	0.000446	CcSEcCtD
Rifaximin—Arthralgia—Capecitabine—kidney cancer	0.000104	0.000446	CcSEcCtD
Rifaximin—Pain—Paclitaxel—kidney cancer	0.000104	0.000445	CcSEcCtD
Rifaximin—Constipation—Paclitaxel—kidney cancer	0.000104	0.000445	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000103	0.000443	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000103	0.000442	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—kidney cancer	0.000103	0.000441	CcSEcCtD
Rifaximin—Discomfort—Capecitabine—kidney cancer	0.000103	0.00044	CcSEcCtD
Rifaximin—Pruritus—Gemcitabine—kidney cancer	0.000103	0.00044	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—kidney cancer	0.000102	0.000438	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—kidney cancer	0.000102	0.000437	CcSEcCtD
Rifaximin—Dry mouth—Capecitabine—kidney cancer	0.000102	0.000436	CcSEcCtD
Rifaximin—Nausea—Dactinomycin—kidney cancer	0.000102	0.000436	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—kidney cancer	0.000101	0.000434	CcSEcCtD
Rifaximin—Dizziness—Vincristine—kidney cancer	0.000101	0.000433	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—kidney cancer	0.000101	0.000432	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—kidney cancer	0.000101	0.000432	CcSEcCtD
Rifaximin—Confusional state—Capecitabine—kidney cancer	0.000101	0.000431	CcSEcCtD
Rifaximin—Feeling abnormal—Paclitaxel—kidney cancer	0.0001	0.000429	CcSEcCtD
Rifaximin—Gastrointestinal pain—Paclitaxel—kidney cancer	9.95e-05	0.000426	CcSEcCtD
Rifaximin—Diarrhoea—Gemcitabine—kidney cancer	9.94e-05	0.000425	CcSEcCtD
Rifaximin—Infection—Capecitabine—kidney cancer	9.92e-05	0.000424	CcSEcCtD
Rifaximin—Shock—Capecitabine—kidney cancer	9.82e-05	0.00042	CcSEcCtD
Rifaximin—Nervous system disorder—Capecitabine—kidney cancer	9.79e-05	0.000419	CcSEcCtD
Rifaximin—Vomiting—Vincristine—kidney cancer	9.74e-05	0.000417	CcSEcCtD
Rifaximin—Skin disorder—Capecitabine—kidney cancer	9.7e-05	0.000415	CcSEcCtD
Rifaximin—Urticaria—Paclitaxel—kidney cancer	9.66e-05	0.000414	CcSEcCtD
Rifaximin—Rash—Vincristine—kidney cancer	9.66e-05	0.000413	CcSEcCtD
Rifaximin—Hyperhidrosis—Capecitabine—kidney cancer	9.65e-05	0.000413	CcSEcCtD
Rifaximin—Dermatitis—Vincristine—kidney cancer	9.65e-05	0.000413	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—kidney cancer	9.62e-05	0.000412	CcSEcCtD
Rifaximin—Abdominal pain—Paclitaxel—kidney cancer	9.62e-05	0.000412	CcSEcCtD
Rifaximin—Body temperature increased—Paclitaxel—kidney cancer	9.62e-05	0.000412	CcSEcCtD
Rifaximin—Headache—Vincristine—kidney cancer	9.6e-05	0.000411	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—kidney cancer	9.52e-05	0.000407	CcSEcCtD
Rifaximin—Anorexia—Capecitabine—kidney cancer	9.52e-05	0.000407	CcSEcCtD
Rifaximin—Hypotension—Capecitabine—kidney cancer	9.33e-05	0.000399	CcSEcCtD
Rifaximin—Vomiting—Gemcitabine—kidney cancer	9.24e-05	0.000395	CcSEcCtD
Rifaximin—Rash—Gemcitabine—kidney cancer	9.16e-05	0.000392	CcSEcCtD
Rifaximin—Dermatitis—Gemcitabine—kidney cancer	9.15e-05	0.000392	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—kidney cancer	9.1e-05	0.00039	CcSEcCtD
Rifaximin—Headache—Gemcitabine—kidney cancer	9.1e-05	0.00039	CcSEcCtD
Rifaximin—Nausea—Vincristine—kidney cancer	9.1e-05	0.000389	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Capecitabine—kidney cancer	9.1e-05	0.000389	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—kidney cancer	9.08e-05	0.000389	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—kidney cancer	9.06e-05	0.000388	CcSEcCtD
Rifaximin—Insomnia—Capecitabine—kidney cancer	9.03e-05	0.000386	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—kidney cancer	9.01e-05	0.000386	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—kidney cancer	8.99e-05	0.000385	CcSEcCtD
Rifaximin—Hypersensitivity—Paclitaxel—kidney cancer	8.96e-05	0.000384	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—kidney cancer	8.95e-05	0.000383	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—kidney cancer	8.92e-05	0.000382	CcSEcCtD
Rifaximin—Dyspnoea—Capecitabine—kidney cancer	8.9e-05	0.000381	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—kidney cancer	8.88e-05	0.00038	CcSEcCtD
Rifaximin—Asthenia—Paclitaxel—kidney cancer	8.73e-05	0.000374	CcSEcCtD
Rifaximin—Decreased appetite—Capecitabine—kidney cancer	8.68e-05	0.000371	CcSEcCtD
Rifaximin—Nausea—Gemcitabine—kidney cancer	8.63e-05	0.000369	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Capecitabine—kidney cancer	8.62e-05	0.000369	CcSEcCtD
Rifaximin—Fatigue—Capecitabine—kidney cancer	8.61e-05	0.000368	CcSEcCtD
Rifaximin—Pruritus—Paclitaxel—kidney cancer	8.61e-05	0.000368	CcSEcCtD
Rifaximin—Pain—Capecitabine—kidney cancer	8.54e-05	0.000365	CcSEcCtD
Rifaximin—Constipation—Capecitabine—kidney cancer	8.54e-05	0.000365	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—kidney cancer	8.45e-05	0.000361	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—kidney cancer	8.41e-05	0.00036	CcSEcCtD
Rifaximin—Diarrhoea—Paclitaxel—kidney cancer	8.32e-05	0.000356	CcSEcCtD
Rifaximin—Feeling abnormal—Capecitabine—kidney cancer	8.23e-05	0.000352	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—kidney cancer	8.22e-05	0.000352	CcSEcCtD
Rifaximin—Gastrointestinal pain—Capecitabine—kidney cancer	8.16e-05	0.000349	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—kidney cancer	8.16e-05	0.000349	CcSEcCtD
Rifaximin—Dizziness—Paclitaxel—kidney cancer	8.04e-05	0.000344	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—kidney cancer	7.94e-05	0.00034	CcSEcCtD
Rifaximin—Urticaria—Capecitabine—kidney cancer	7.93e-05	0.000339	CcSEcCtD
Rifaximin—Abdominal pain—Capecitabine—kidney cancer	7.89e-05	0.000338	CcSEcCtD
Rifaximin—Body temperature increased—Capecitabine—kidney cancer	7.89e-05	0.000338	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—kidney cancer	7.88e-05	0.000337	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—kidney cancer	7.77e-05	0.000332	CcSEcCtD
Rifaximin—Vomiting—Paclitaxel—kidney cancer	7.73e-05	0.000331	CcSEcCtD
Rifaximin—Rash—Paclitaxel—kidney cancer	7.67e-05	0.000328	CcSEcCtD
Rifaximin—Dermatitis—Paclitaxel—kidney cancer	7.66e-05	0.000328	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—kidney cancer	7.63e-05	0.000326	CcSEcCtD
Rifaximin—Headache—Paclitaxel—kidney cancer	7.62e-05	0.000326	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—kidney cancer	7.58e-05	0.000324	CcSEcCtD
Rifaximin—Hypersensitivity—Capecitabine—kidney cancer	7.36e-05	0.000315	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—kidney cancer	7.32e-05	0.000313	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—kidney cancer	7.29e-05	0.000312	CcSEcCtD
Rifaximin—Nausea—Paclitaxel—kidney cancer	7.23e-05	0.000309	CcSEcCtD
Rifaximin—Asthenia—Capecitabine—kidney cancer	7.16e-05	0.000307	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—kidney cancer	7.11e-05	0.000304	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—kidney cancer	7.08e-05	0.000303	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—kidney cancer	7.07e-05	0.000303	CcSEcCtD
Rifaximin—Pruritus—Capecitabine—kidney cancer	7.06e-05	0.000302	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—kidney cancer	6.93e-05	0.000297	CcSEcCtD
Rifaximin—Cough—Doxorubicin—kidney cancer	6.88e-05	0.000294	CcSEcCtD
Rifaximin—Diarrhoea—Capecitabine—kidney cancer	6.83e-05	0.000292	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—kidney cancer	6.71e-05	0.000287	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—kidney cancer	6.71e-05	0.000287	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—kidney cancer	6.71e-05	0.000287	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	6.67e-05	0.000285	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—kidney cancer	6.63e-05	0.000284	CcSEcCtD
Rifaximin—Dizziness—Capecitabine—kidney cancer	6.6e-05	0.000283	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—kidney cancer	6.57e-05	0.000281	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—kidney cancer	6.49e-05	0.000278	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—kidney cancer	6.44e-05	0.000275	CcSEcCtD
Rifaximin—Infection—Doxorubicin—kidney cancer	6.39e-05	0.000274	CcSEcCtD
Rifaximin—Vomiting—Capecitabine—kidney cancer	6.35e-05	0.000272	CcSEcCtD
Rifaximin—Shock—Doxorubicin—kidney cancer	6.33e-05	0.000271	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—kidney cancer	6.31e-05	0.00027	CcSEcCtD
Rifaximin—Rash—Capecitabine—kidney cancer	6.29e-05	0.000269	CcSEcCtD
Rifaximin—Dermatitis—Capecitabine—kidney cancer	6.29e-05	0.000269	CcSEcCtD
Rifaximin—Headache—Capecitabine—kidney cancer	6.25e-05	0.000268	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—kidney cancer	6.25e-05	0.000267	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—kidney cancer	6.22e-05	0.000266	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—kidney cancer	6.13e-05	0.000262	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—kidney cancer	6.01e-05	0.000257	CcSEcCtD
Rifaximin—Nausea—Capecitabine—kidney cancer	5.93e-05	0.000254	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.86e-05	0.000251	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—kidney cancer	5.82e-05	0.000249	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—kidney cancer	5.74e-05	0.000246	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—kidney cancer	5.59e-05	0.000239	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.56e-05	0.000238	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—kidney cancer	5.55e-05	0.000237	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—kidney cancer	5.5e-05	0.000235	CcSEcCtD
Rifaximin—Pain—Doxorubicin—kidney cancer	5.5e-05	0.000235	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—kidney cancer	5.3e-05	0.000227	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—kidney cancer	5.26e-05	0.000225	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—kidney cancer	5.11e-05	0.000219	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—kidney cancer	5.09e-05	0.000218	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—kidney cancer	5.09e-05	0.000218	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—kidney cancer	4.74e-05	0.000203	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—kidney cancer	4.62e-05	0.000198	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—kidney cancer	4.55e-05	0.000195	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—kidney cancer	4.4e-05	0.000188	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—kidney cancer	4.26e-05	0.000182	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—kidney cancer	4.09e-05	0.000175	CcSEcCtD
Rifaximin—Rash—Doxorubicin—kidney cancer	4.06e-05	0.000174	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—kidney cancer	4.05e-05	0.000173	CcSEcCtD
Rifaximin—Headache—Doxorubicin—kidney cancer	4.03e-05	0.000173	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—kidney cancer	3.82e-05	0.000164	CcSEcCtD
